Search Results - "Homicskó, K."

Turning tumors from cold to inflamed to improve immunotherapy response by Gerard, C.L., Delyon, J., Wicky, A., Homicsko, K., Cuendet, Michel A., Michielin, O.

“…[Display omitted] •New strategies to turn cold tumors into T cell-inflamed tumors are emerging, holding great promises to extend the benefits of…”
Get full text

Salsolinol is a Putative Endogenous Neuro-intermediate Lobe Prolactin-Releasing Factor by Tóth, B. E., Homicskó, K., Radnai, B., Maruyama, W., DeMaria, J. E., Vecsernyés, M., Fekete, M. I. K., Fülöp, F., Naoi, M., Freeman, M. E., Nagy, G. M.

“…The isolation and identification of a prolactin‐releasing factor (PRF) from the neuro‐intermediate lobe of the pituitary gland has been pursued for over a…”
Get full text

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy by Ghisoni, E., Wicky, A., Bouchaab, H., Imbimbo, M., Delyon, J., Gautron Moura, B., Gérard, C.L., Latifyan, S., Özdemir, B.C., Caikovski, M., Pradervand, S., Tavazzi, E., Gatta, R., Marandino, L., Valabrega, G., Aglietta, M., Obeid, M., Homicsko, K., Mederos Alfonso, N.N., Zimmermann, S., Coukos, G., Peters, S., Cuendet, M.A., Di Maio, M., Michielin, O.

“…Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy but frequently cause immune-related adverse events (irAEs). Description of late-onset…”
Get full text

B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma by Gavrielatou, N, Fortis, E, Spathis, A, Anastasiou, M, Economopoulou, P, Foukas, G R P, Lelegiannis, I M, Rusakiewicz, S, Vathiotis, I, Aung, T N, Tissot, S, Kastrinou, A, Kotsantis, I, Vagia, E M, Panayiotides, I, Rimm, D L, Coukos, G, Homicsko, K, Foukas, P, Psyrri, A

“…Programmed cell death protein 1 (PD-1) axis blockade has become the mainstay in the treatment of recurrent and/or metastatic (R/M) head and neck squamous cell…”
Get more information

3356 Triple wild type melanoma profiling in the Caris Molecular IntelligenceTM registry by Homicsko, K, Kenneth, R, Voss, A, Michielin, O

Get full text

Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches by Digklia, A., Duran, R., Homicsko, K., Kandalaft, L. E., Hocquelet, A., Orcurto, A., Coukos, G., Denys, A.

“…The therapeutic options in the treatment of cancer therapy have been recently significantly increased with systemic immune-targeted therapies. Novel…”
Get full text

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors by Stathis, A., Hess, D., von Moos, R., Homicsko, K., Griguolo, G., Joerger, M., Mark, M., Ackermann, C. J., Allegrini, S., Catapano, C. V., Xyrafas, A., Enoiu, M., Berardi, S., Gargiulo, P., Sessa, C.

“…Summary Purpose To establish a recommended phase II dose (RP2D) for the oral smoothened inhibitor sonidegib in combination with paclitaxel; secondary…”
Get full text

Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients by Homicsko, K., Richtig, G., Tuchmann, F., Tsourti, Z., Hanahan, D., Coukos, G., Wind-Rotolo, M., Richtig, E., Zygoura, P., Holler, C., Dafni, U., Michielin, O.A.

Get full text

Compact solid-state CMOS single-photon detector array for in vivo NIR fluorescence lifetime oncology measurements by Homulle, H A R, Powolny, F, Stegehuis, P L, Dijkstra, J, Li, D-U, Homicsko, K, Rimoldi, D, Muehlethaler, K, Prior, J O, Sinisi, R, Dubikovskaya, E, Charbon, E, Bruschini, C

“…In near infrared fluorescence-guided surgical oncology, it is challenging to distinguish healthy from cancerous tissue. One promising research avenue consists…”
Get full text

A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC) by O’Cearbhaill, R.E., Wolfer, A., Disilvestro, P., O’Malley, D.M., Sabbatini, P., Shohara, L., Schwarzenberger, P.O., Ricciardi, T., Macri, M., Ryan, A., Venhaus, R.R., Bryan, J.K., Wong, P., Homicsko, K., Kandalaft, L., Rusakiewicz, S., Harari, A., Monk, B.J., Coukos, G.

Get full text

Decision making and management of gliomas: practical considerations by Hottinger, A F, Homicsko, K, Negretti, L, Lhermitte, B, Stupp, R

“…Over the last decade, diagnostic options and introduction of novel treatments have expanded the armamentarium in the management of malignant glioma. Combined…”
Get full text

340 A phase I study of the smoothened (SMO) antagonist LDE225 in combination with paclitaxel in patients with advanced solid tumors by Stathis, A, Hess, D, Xyrafas, A, Enoiu, M, Berardi, S, Moos, R. Von, Homicsko, K, Griguolo, G, Jörger, M, Mark, M, Ackermann, C, Sessa, C

Get full text

505 Clinical evidence of intra-tumoral immune activation and tumor targeting with RG, a CEA-targeted engineered IL-2 immunocytokine by Tabernero, J, Homicsko, K, Schellens, J.H, Hoekstra, O, Van der Veen, L, Melero, I, és, G. Argil, Mau-Sorensen, M, Angevin, E, Joensuu, H, Van Brummelen, E, van Oordt, C.W. Menke-van der Houven, Nayak, T, Romagnoli, S, Reis, B, Brossard, S. Soehrman, Evers, S, Saro, J, Verheul, H, Lassen, U

Get full text

Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus by Bazan-Peregrino, M, Carlisle, R C, Hernandez-Alcoceba, R, Iggo, R, Homicsko, K, Fisher, K D, Halldén, G, Mautner, V, Shen, Y, Seymour, L W

“…Oncolytic viruses are regulated by the tumor phenotype to replicate and lyse cancer cells selectively. To identify optimal strategies for breast cancer we…”
Get more information

2278P Endothelial cell heterogeneity defined by single-cell spatial transcriptomic analysis of breast cancers by Homicsko, K., Zaman, K., Stravodimou, A.

Get full text

28INNEW MOLECULAR CLASSIFICATION OF COLORECTAL CANCER by Homicsko, K., Sadanandam, A.

“…Abstract Colorectal cancer (CRC) is a heterogeneous disease, and currently only Ras mutation status is available to predict treatment responses for a small…”
Get full text

New Molecular Classification of Colorectal Cancer by Homicsko, K., Sadanandam, A.

Get full text

4OTumour cells mirror embryonic developmental programs to acquire invasive and metastatic capabilities by Saghafinia, S, Michael, I, Homicsko, K, Hanahan, D

“…Abstract Background Pancreatic Neuroendocrine Tumours (PanNETs) are the second most common form of pancreatic cancer. We previously identified two principal…”
Get full text

Tumour cells mirror embryonic developmental programs to acquire invasive and metastatic capabilities by Saghafinia, S., Michael, I., Homicsko, K., Hanahan, D.

Get full text

121 (PB109): TT125-802, a highly selective bromodomain inhibitor of CBP/p300, in patients with advanced solid tumors: an update on the phase I study by Boni, V., Antras, J. Fuentes, Garralda, E., Saavedra, O., Colombo, I., Stathis, A., Homicsko, K., Braña, I., Costanzo, S., Gruber, D., Cesano, A., Flückiger-Mangual, S.

Get full text